nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—CYP1A1—kidney cancer	0.00231	0.653	CrCbGaD
Apraclonidine—Asthenia—Vinblastine—kidney cancer	0.00135	0.00136	CcSEcCtD
Apraclonidine—Fatigue—Sunitinib—kidney cancer	0.00135	0.00136	CcSEcCtD
Apraclonidine—Asthenia—Everolimus—kidney cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Angiopathy—Paclitaxel—kidney cancer	0.00134	0.00135	CcSEcCtD
Apraclonidine—Pain—Sunitinib—kidney cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Constipation—Sunitinib—kidney cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Mediastinal disorder—Paclitaxel—kidney cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sorafenib—kidney cancer	0.00133	0.00134	CcSEcCtD
Apraclonidine—Pruritus—Everolimus—kidney cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Oedema—Vincristine—kidney cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Arrhythmia—Paclitaxel—kidney cancer	0.00132	0.00133	CcSEcCtD
Apraclonidine—Infection—Vincristine—kidney cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Conjunctivitis—Capecitabine—kidney cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Chest pain—Gemcitabine—kidney cancer	0.00131	0.00132	CcSEcCtD
Apraclonidine—Myalgia—Gemcitabine—kidney cancer	0.00131	0.00132	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.0013	0.00131	CcSEcCtD
Apraclonidine—Nervous system disorder—Vincristine—kidney cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Asthenia—Erlotinib—kidney cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Mental disorder—Paclitaxel—kidney cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Discomfort—Gemcitabine—kidney cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Erythema—Paclitaxel—kidney cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Diarrhoea—Vinblastine—kidney cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Abdominal pain—Sorafenib—kidney cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Diarrhoea—Everolimus—kidney cancer	0.00128	0.00129	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sunitinib—kidney cancer	0.00128	0.00129	CcSEcCtD
Apraclonidine—Pruritus—Erlotinib—kidney cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—kidney cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—kidney cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Tension—Paclitaxel—kidney cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Dysgeusia—Paclitaxel—kidney cancer	0.00126	0.00127	CcSEcCtD
Apraclonidine—Oedema—Gemcitabine—kidney cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—kidney cancer	0.00125	0.00126	CcSEcCtD
Apraclonidine—Nervousness—Paclitaxel—kidney cancer	0.00125	0.00126	CcSEcCtD
Apraclonidine—Infection—Gemcitabine—kidney cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Dizziness—Vinblastine—kidney cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Dizziness—Everolimus—kidney cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Abdominal pain—Sunitinib—kidney cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Diarrhoea—Erlotinib—kidney cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Bradycardia—Capecitabine—kidney cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Nervous system disorder—Gemcitabine—kidney cancer	0.00123	0.00124	CcSEcCtD
Apraclonidine—Clonidine—ABCB1—kidney cancer	0.00123	0.347	CrCbGaD
Apraclonidine—Feeling abnormal—Dactinomycin—kidney cancer	0.00122	0.00123	CcSEcCtD
Apraclonidine—Skin disorder—Gemcitabine—kidney cancer	0.00122	0.00123	CcSEcCtD
Apraclonidine—Rhinitis—Capecitabine—kidney cancer	0.00122	0.00122	CcSEcCtD
Apraclonidine—Haemorrhage—Capecitabine—kidney cancer	0.00122	0.00122	CcSEcCtD
Apraclonidine—Vision blurred—Paclitaxel—kidney cancer	0.00122	0.00122	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00121	0.00122	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Pharyngitis—Capecitabine—kidney cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Hypersensitivity—Sorafenib—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Insomnia—Vincristine—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Oedema peripheral—Capecitabine—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Vomiting—Vinblastine—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Dizziness—Erlotinib—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Ill-defined disorder—Paclitaxel—kidney cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Vomiting—Everolimus—kidney cancer	0.00119	0.0012	CcSEcCtD
Apraclonidine—Paraesthesia—Vincristine—kidney cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Dermatitis—Everolimus—kidney cancer	0.00118	0.00119	CcSEcCtD
Apraclonidine—Headache—Vinblastine—kidney cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Headache—Everolimus—kidney cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—kidney cancer	0.00117	0.00118	CcSEcCtD
Apraclonidine—Visual impairment—Capecitabine—kidney cancer	0.00117	0.00118	CcSEcCtD
Apraclonidine—Asthenia—Sorafenib—kidney cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Malaise—Paclitaxel—kidney cancer	0.00116	0.00117	CcSEcCtD
Apraclonidine—Syncope—Paclitaxel—kidney cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Hypersensitivity—Sunitinib—kidney cancer	0.00115	0.00116	CcSEcCtD
Apraclonidine—Pruritus—Sorafenib—kidney cancer	0.00115	0.00116	CcSEcCtD
Apraclonidine—Vomiting—Erlotinib—kidney cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vincristine—kidney cancer	0.00114	0.00115	CcSEcCtD
Apraclonidine—Fatigue—Vincristine—kidney cancer	0.00114	0.00115	CcSEcCtD
Apraclonidine—Dermatitis—Erlotinib—kidney cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Palpitations—Paclitaxel—kidney cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Insomnia—Gemcitabine—kidney cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Eye disorder—Capecitabine—kidney cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Headache—Erlotinib—kidney cancer	0.00113	0.00114	CcSEcCtD
Apraclonidine—Pain—Vincristine—kidney cancer	0.00113	0.00114	CcSEcCtD
Apraclonidine—Constipation—Vincristine—kidney cancer	0.00113	0.00114	CcSEcCtD
Apraclonidine—Paraesthesia—Gemcitabine—kidney cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Asthenia—Sunitinib—kidney cancer	0.00112	0.00113	CcSEcCtD
Apraclonidine—Dyspnoea—Gemcitabine—kidney cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Nausea—Vinblastine—kidney cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Somnolence—Gemcitabine—kidney cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Nausea—Everolimus—kidney cancer	0.00111	0.00112	CcSEcCtD
Apraclonidine—Diarrhoea—Sorafenib—kidney cancer	0.00111	0.00112	CcSEcCtD
Apraclonidine—Pruritus—Sunitinib—kidney cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Angiopathy—Capecitabine—kidney cancer	0.0011	0.00111	CcSEcCtD
Apraclonidine—Myalgia—Paclitaxel—kidney cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Chest pain—Paclitaxel—kidney cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Mediastinal disorder—Capecitabine—kidney cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—kidney cancer	0.00109	0.0011	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—kidney cancer	0.00109	0.0011	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Arrhythmia—Capecitabine—kidney cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Discomfort—Paclitaxel—kidney cancer	0.00108	0.00109	CcSEcCtD
Apraclonidine—Fatigue—Gemcitabine—kidney cancer	0.00108	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vincristine—kidney cancer	0.00108	0.00109	CcSEcCtD
Apraclonidine—Dizziness—Sorafenib—kidney cancer	0.00108	0.00108	CcSEcCtD
Apraclonidine—Constipation—Gemcitabine—kidney cancer	0.00107	0.00108	CcSEcCtD
Apraclonidine—Pain—Gemcitabine—kidney cancer	0.00107	0.00108	CcSEcCtD
Apraclonidine—Nausea—Erlotinib—kidney cancer	0.00107	0.00108	CcSEcCtD
Apraclonidine—Dry mouth—Paclitaxel—kidney cancer	0.00107	0.00108	CcSEcCtD
Apraclonidine—Diarrhoea—Sunitinib—kidney cancer	0.00107	0.00108	CcSEcCtD
Apraclonidine—Mental disorder—Capecitabine—kidney cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—kidney cancer	0.00106	0.00107	CcSEcCtD
Apraclonidine—Erythema—Capecitabine—kidney cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Oedema—Paclitaxel—kidney cancer	0.00105	0.00106	CcSEcCtD
Apraclonidine—Abdominal pain—Vincristine—kidney cancer	0.00105	0.00105	CcSEcCtD
Apraclonidine—Infection—Paclitaxel—kidney cancer	0.00105	0.00105	CcSEcCtD
Apraclonidine—Dysgeusia—Capecitabine—kidney cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Dizziness—Sunitinib—kidney cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Feeling abnormal—Gemcitabine—kidney cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Vomiting—Sorafenib—kidney cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Nervous system disorder—Paclitaxel—kidney cancer	0.00103	0.00104	CcSEcCtD
Apraclonidine—Dermatitis—Sorafenib—kidney cancer	0.00103	0.00103	CcSEcCtD
Apraclonidine—Skin disorder—Paclitaxel—kidney cancer	0.00102	0.00103	CcSEcCtD
Apraclonidine—Headache—Sorafenib—kidney cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—kidney cancer	0.00101	0.00102	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—kidney cancer	0.00101	0.00102	CcSEcCtD
Apraclonidine—Vision blurred—Capecitabine—kidney cancer	0.000997	0.001	CcSEcCtD
Apraclonidine—Vomiting—Sunitinib—kidney cancer	0.000996	0.001	CcSEcCtD
Apraclonidine—Dermatitis—Sunitinib—kidney cancer	0.000987	0.00099	CcSEcCtD
Apraclonidine—Ill-defined disorder—Capecitabine—kidney cancer	0.000982	0.000985	CcSEcCtD
Apraclonidine—Headache—Sunitinib—kidney cancer	0.000981	0.000985	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—kidney cancer	0.000979	0.000982	CcSEcCtD
Apraclonidine—Hypersensitivity—Vincristine—kidney cancer	0.000976	0.00098	CcSEcCtD
Apraclonidine—Nausea—Sorafenib—kidney cancer	0.000967	0.000971	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000959	0.000962	CcSEcCtD
Apraclonidine—Malaise—Capecitabine—kidney cancer	0.000954	0.000958	CcSEcCtD
Apraclonidine—Insomnia—Paclitaxel—kidney cancer	0.000952	0.000955	CcSEcCtD
Apraclonidine—Asthenia—Vincristine—kidney cancer	0.000951	0.000954	CcSEcCtD
Apraclonidine—Syncope—Capecitabine—kidney cancer	0.000949	0.000952	CcSEcCtD
Apraclonidine—Paraesthesia—Paclitaxel—kidney cancer	0.000945	0.000948	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—kidney cancer	0.000943	0.000946	CcSEcCtD
Apraclonidine—Dyspnoea—Paclitaxel—kidney cancer	0.000938	0.000942	CcSEcCtD
Apraclonidine—Somnolence—Paclitaxel—kidney cancer	0.000936	0.000939	CcSEcCtD
Apraclonidine—Palpitations—Capecitabine—kidney cancer	0.000935	0.000939	CcSEcCtD
Apraclonidine—Nausea—Sunitinib—kidney cancer	0.000931	0.000934	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000909	0.000912	CcSEcCtD
Apraclonidine—Fatigue—Paclitaxel—kidney cancer	0.000907	0.000911	CcSEcCtD
Apraclonidine—Diarrhoea—Vincristine—kidney cancer	0.000907	0.00091	CcSEcCtD
Apraclonidine—Asthenia—Gemcitabine—kidney cancer	0.000902	0.000905	CcSEcCtD
Apraclonidine—Chest pain—Capecitabine—kidney cancer	0.000901	0.000904	CcSEcCtD
Apraclonidine—Myalgia—Capecitabine—kidney cancer	0.000901	0.000904	CcSEcCtD
Apraclonidine—Pain—Paclitaxel—kidney cancer	0.0009	0.000903	CcSEcCtD
Apraclonidine—Constipation—Paclitaxel—kidney cancer	0.0009	0.000903	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000895	0.000898	CcSEcCtD
Apraclonidine—Discomfort—Capecitabine—kidney cancer	0.00089	0.000893	CcSEcCtD
Apraclonidine—Pruritus—Gemcitabine—kidney cancer	0.000889	0.000893	CcSEcCtD
Apraclonidine—Dry mouth—Capecitabine—kidney cancer	0.000881	0.000884	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—kidney cancer	0.000881	0.000884	CcSEcCtD
Apraclonidine—Dizziness—Vincristine—kidney cancer	0.000876	0.000879	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—kidney cancer	0.000873	0.000876	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—kidney cancer	0.000873	0.000876	CcSEcCtD
Apraclonidine—Feeling abnormal—Paclitaxel—kidney cancer	0.000867	0.00087	CcSEcCtD
Apraclonidine—Oedema—Capecitabine—kidney cancer	0.000864	0.000867	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000861	0.000864	CcSEcCtD
Apraclonidine—Diarrhoea—Gemcitabine—kidney cancer	0.00086	0.000863	CcSEcCtD
Apraclonidine—Infection—Capecitabine—kidney cancer	0.000858	0.000861	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—kidney cancer	0.000849	0.000852	CcSEcCtD
Apraclonidine—Nervous system disorder—Capecitabine—kidney cancer	0.000847	0.00085	CcSEcCtD
Apraclonidine—Vomiting—Vincristine—kidney cancer	0.000843	0.000845	CcSEcCtD
Apraclonidine—Skin disorder—Capecitabine—kidney cancer	0.000839	0.000842	CcSEcCtD
Apraclonidine—Dermatitis—Vincristine—kidney cancer	0.000835	0.000838	CcSEcCtD
Apraclonidine—Abdominal pain—Paclitaxel—kidney cancer	0.000832	0.000835	CcSEcCtD
Apraclonidine—Headache—Vincristine—kidney cancer	0.00083	0.000833	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—kidney cancer	0.000799	0.000802	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—kidney cancer	0.000798	0.000801	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—kidney cancer	0.000792	0.000795	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—kidney cancer	0.000788	0.00079	CcSEcCtD
Apraclonidine—Nausea—Vincristine—kidney cancer	0.000787	0.00079	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000787	0.00079	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—kidney cancer	0.000786	0.000788	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—kidney cancer	0.000784	0.000786	CcSEcCtD
Apraclonidine—Insomnia—Capecitabine—kidney cancer	0.000781	0.000784	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—kidney cancer	0.000778	0.000781	CcSEcCtD
Apraclonidine—Paraesthesia—Capecitabine—kidney cancer	0.000776	0.000778	CcSEcCtD
Apraclonidine—Hypersensitivity—Paclitaxel—kidney cancer	0.000775	0.000778	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—kidney cancer	0.000772	0.000775	CcSEcCtD
Apraclonidine—Dyspnoea—Capecitabine—kidney cancer	0.00077	0.000773	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—kidney cancer	0.000755	0.000758	CcSEcCtD
Apraclonidine—Asthenia—Paclitaxel—kidney cancer	0.000755	0.000758	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—kidney cancer	0.000747	0.000749	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000746	0.000748	CcSEcCtD
Apraclonidine—Fatigue—Capecitabine—kidney cancer	0.000745	0.000747	CcSEcCtD
Apraclonidine—Pruritus—Paclitaxel—kidney cancer	0.000745	0.000747	CcSEcCtD
Apraclonidine—Pain—Capecitabine—kidney cancer	0.000739	0.000741	CcSEcCtD
Apraclonidine—Constipation—Capecitabine—kidney cancer	0.000739	0.000741	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—kidney cancer	0.000732	0.000735	CcSEcCtD
Apraclonidine—Diarrhoea—Paclitaxel—kidney cancer	0.00072	0.000723	CcSEcCtD
Apraclonidine—Feeling abnormal—Capecitabine—kidney cancer	0.000712	0.000714	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—kidney cancer	0.000711	0.000713	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000706	0.000709	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000706	0.000709	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—kidney cancer	0.0007	0.000703	CcSEcCtD
Apraclonidine—Dizziness—Paclitaxel—kidney cancer	0.000696	0.000698	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—kidney cancer	0.000687	0.000689	CcSEcCtD
Apraclonidine—Abdominal pain—Capecitabine—kidney cancer	0.000683	0.000685	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—kidney cancer	0.000682	0.000685	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—kidney cancer	0.000669	0.000672	CcSEcCtD
Apraclonidine—Vomiting—Paclitaxel—kidney cancer	0.000669	0.000672	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—kidney cancer	0.000668	0.00067	CcSEcCtD
Apraclonidine—Dermatitis—Paclitaxel—kidney cancer	0.000663	0.000665	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—kidney cancer	0.000663	0.000665	CcSEcCtD
Apraclonidine—Headache—Paclitaxel—kidney cancer	0.000659	0.000662	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—kidney cancer	0.000643	0.000645	CcSEcCtD
Apraclonidine—Hypersensitivity—Capecitabine—kidney cancer	0.000636	0.000639	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—kidney cancer	0.000633	0.000635	CcSEcCtD
Apraclonidine—Nausea—Paclitaxel—kidney cancer	0.000625	0.000627	CcSEcCtD
Apraclonidine—Asthenia—Capecitabine—kidney cancer	0.00062	0.000622	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—kidney cancer	0.000615	0.000617	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—kidney cancer	0.000612	0.000614	CcSEcCtD
Apraclonidine—Pruritus—Capecitabine—kidney cancer	0.000611	0.000613	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—kidney cancer	0.000603	0.000605	CcSEcCtD
Apraclonidine—Diarrhoea—Capecitabine—kidney cancer	0.000591	0.000593	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—kidney cancer	0.000581	0.000583	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—kidney cancer	0.000581	0.000583	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000577	0.000579	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—kidney cancer	0.000574	0.000576	CcSEcCtD
Apraclonidine—Dizziness—Capecitabine—kidney cancer	0.000571	0.000573	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—kidney cancer	0.000568	0.00057	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—kidney cancer	0.000557	0.000559	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—kidney cancer	0.000553	0.000555	CcSEcCtD
Apraclonidine—Vomiting—Capecitabine—kidney cancer	0.000549	0.000551	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—kidney cancer	0.000546	0.000548	CcSEcCtD
Apraclonidine—Dermatitis—Capecitabine—kidney cancer	0.000544	0.000546	CcSEcCtD
Apraclonidine—Headache—Capecitabine—kidney cancer	0.000541	0.000543	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—kidney cancer	0.000541	0.000543	CcSEcCtD
Apraclonidine—Nausea—Capecitabine—kidney cancer	0.000513	0.000515	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000507	0.000509	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—kidney cancer	0.000504	0.000505	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—kidney cancer	0.0005	0.000502	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—kidney cancer	0.000496	0.000498	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—kidney cancer	0.000495	0.000497	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000481	0.000482	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—kidney cancer	0.00048	0.000482	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—kidney cancer	0.000476	0.000478	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—kidney cancer	0.000476	0.000478	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—kidney cancer	0.000459	0.00046	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000455	0.000457	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—kidney cancer	0.00044	0.000442	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—kidney cancer	0.00041	0.000412	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—kidney cancer	0.000399	0.000401	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—kidney cancer	0.000394	0.000395	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—kidney cancer	0.000381	0.000382	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—kidney cancer	0.000368	0.000369	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—kidney cancer	0.000354	0.000355	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—kidney cancer	0.000351	0.000352	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—kidney cancer	0.000349	0.00035	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—kidney cancer	0.000331	0.000332	CcSEcCtD
